Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States

References

• American Cancer Society. What is chronic lymphocytic leukemia? 2018. Available at: https://www.cancer.org/cancer/chronic-lymphocytic-leukemia/about/what-is-cll.html. Accessed: Nov 17, 2022.
   Google Scholar
• American Society of Clinical Oncology. Leukemia - chronic lymphocytic - CLL: statistics. 2021. Available at: https://www.cancer.net/cancer-types/leukemia-chronic-lymphocytic-cll/statistics. Accessed: Nov 17, 2022.
   Google Scholar
• Goyal RK, Nagar SP, Kabadi SM, et al. Overall survival, adverse events, and economic burden in patients with chronic lymphocytic leukemia receiving systemic therapy: real-world evidence from the medicare population. Cancer Med. 2021;10(8):2690–2702. DOI:10.1002/cam4.3855.
   PubMed Web of Science ®Google Scholar
• Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. DOI:10.1056/NEJMoa1812836.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. SEER cancer stat facts: leukemia - chronic lymphocytic leukemia. 2022. Available at: https://seer.cancer.gov/statfacts/html/clyl.html. Accessed: Nov 17, 2022.
   Google Scholar
• Calquence [package insert]. Wilmington DE;AstraZeneca Pharmaceuticals. Aug 2022.
   Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291. DOI:10.1016/S0140-6736(20)30262-2.
   PubMed Web of Science ®Google Scholar
• Sharman JP, Egyed M, Jurczak W, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36:1171–1175.
   PubMed Web of Science ®Google Scholar
• Smare C, Lakhdari K, Doan J, et al. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97–108. DOI:10.1007/s40273-019-00845-x.
   PubMed Web of Science ®Google Scholar
• Carta A, Conversano C. On the use of Markov models in pharmacoeconomics: pros and cons and implications for policy makers. Front Public Health. 2020;8:569500.
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. ICER’s reference case for economic evaluations: principles and rationale. 2020. Available at: https://icer.org/wp-content/uploads/2020/10/ICER_Reference_Case_013120.pdf. Accessed: Nov 17, 2022.
   Google Scholar
• Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38(25):2849–2861. DOI:10.1200/JCO.19.03355.
   PubMed Web of Science ®Google Scholar
• Latimer N NICE DSU technical support document 14. Survival analysis for economic evaluations alongside clinical trials – extrapolation with patient-level data Sheffield: NICE decision support Unit; 2013 [updated Mar 2013;Aug 3, 2020]. Available at: http://nicedsu.org.uk/wp-content/uploads/2016/03/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf. Accessed: Nov 17, 2022.
   Google Scholar
• Arias E, Xu J. United States Life Tables, 2018. Natl Vital Stat Rep. 2020;69:1–45.
   Google Scholar
• Jurczak W, Pluta A, Wach M, et al. Three-year follow-up of the ASCEND trial: acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia [abstract]. Blood. 2021;138(Supplement 1):393. DOI:10.1182/blood-2021-146570.
   Google Scholar
• National Institute for Health and Care Excellence. Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. 2019. Available at: www.nice.org.uk/guidance/ta561. Accessed: Nov 17, 2022.
   Google Scholar
• IBM Micromedex RED BOOK: iBM Watson Health; 2022 [Jul 8, 2022]. Available at: https://www.ibm.com/products/micromedex-red-book. Accessed: Nov 17, 2022.
   Google Scholar
• Centers for Medicare and Medicaid Services. Search the Physician Fee Schedule. 2022. Available at: https://www.cms.gov/medicare/physician-fee-schedule/search. Accessed: Nov 17, 2022.
   Google Scholar
• Davids MS, Emeribe U, Cai L, et al., editors. Matching-adjusted indirect treatment comparison (MAIC) of acalabrutinib alone or in combination with obinutuzumab versus ibrutinib or venetoclax plus obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia [poster]. Annual Meeting and Exposition of the American Society of Hematology; Dec 11-14, 2021; Atlanta, GA.
   Google Scholar
• Agency for Healthcare Research and Quality. Healthcare cost and utilization project. 2022. Available at: https://hcupnet.ahrq.gov/#setup. Accessed: Nov 17, 2022.
   Google Scholar
• National Institute for Health and Care Excellence. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. 2016. Available at: https://www.nice.org.uk/guidance/ta403. Accessed: Nov 17, 2022.
   Google Scholar
• National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2019. Available at: www.nice.org.uk/guidance/ng115. Accessed: Nov 17, 2022.
   Google Scholar
• Health Resources & Services Administration. Consumer Price Index (CPI) for medical care. 2021. Available at: https://www.hrsa.gov/get-health-care/affordable/hill-burton/cpi.html. Accessed: Nov 17, 2022.
   Google Scholar
• Organisation for Economic Co-operation and Development. Prices and purchasing power parities (PPP). 2022. Available at: https://www.oecd.org/sdd/prices-ppp/. Accessed: Nov 17, 2022.
   Google Scholar
• Munir T, Gaitonde P, Waweru C. Cost-effectiveness of acalabrutinib monotherapy compared with chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukemia [abstract]. Blood. 2020;136(suppl Supplement 1):13–14.
   Google Scholar